key: cord-0018710-mk94u9mp authors: Yang, Xiaoxiao; Lu, Wen; Hopper, Christopher P.; Ke, Bowen; Wang, Binghe title: Nature's marvels endowed in gaseous molecules I: Carbon monoxide and its physiological and therapeutic roles date: 2020-10-16 journal: Acta Pharm Sin B DOI: 10.1016/j.apsb.2020.10.010 sha: 19ea1cb42e2a529bf73561f6ab3e553fea05891d doc_id: 18710 cord_uid: mk94u9mp Nature has endowed gaseous molecules such as O(2), CO(2), CO, NO, H(2)S, and N(2) with critical and diverse roles in sustaining life, from supplying energy needed to power life and building blocks for life's physical structure to mediating and coordinating cellular functions. In this article, we give a brief introduction of the complex functions of the various gaseous molecules in life and then focus on carbon monoxide as a specific example of an endogenously produced signaling molecule to highlight the importance of this class of molecules. The past twenty years have seen much progress in understanding CO's mechanism(s) of action and pharmacological effects as well as in developing delivery methods for easy administration. One remarkable trait of CO is its pleiotropic effects that have few parallels, except perhaps its sister gaseous signaling molecules such as nitric oxide and hydrogen sulfide. This review will delve into the sophistication of CO-mediated signaling as well as its validated pharmacological functions and possible therapeutic applications. There are many ways of looking at life on earth, depending on the specific context. However, at a fifty-thousand-foot view, life needs three key components to sustain: an appropriately organized physical structure, well-coordinated signaling mechanisms to mediate the functions of the physical structure, and energy to power life. Missing any of the three components, life would cease to exist. In modern biology, the discussions of physiological and pathological processes of life commonly (and rightfully) involve the examination of DNA, RNA, proteins, peptides, saccharides, lipids, metal ions, essential nutrients such as amino acids and carbohydrates, and signaling molecules including hormones, neurotransmitters, cytokines, chemokines, metabolites, and other small molecules. Often overlooked is a group of gaseous molecules that play critical roles in sustaining life. With this article, we hope to look at some of the life's processes from a "gas"-centric perspective. As such, we hope to highlight the diverse roles that nature has endowed upon a relatively small number of gaseous molecules by starting with a brief description of how they help to sustain life on a global level, then transitioning to their endogenous signaling roles in mammals, and finally zeroing in on one example, carbon monoxide, to unveil the amazing roles that this small molecule plays in health and disease and its promise as a potential therapeutic agent. If one looks at life on earth, a central issue to consider is how to capture and use energy to power life. Long before atmospheric oxygen was available for aerobic respiration, Earth's atmosphere was abundant with gases such as methane, nitric oxide, hydrogen sulfide, and carbon monoxide, which early life probably harnessed for energy in redox mechanisms 1 . In Earth's modern ecosystem, solar energy is the dominant form of energy sustaining life through photosynthesis. In this context, it is amazing to see how two gaseous molecules serve as the key conduits of energy flow among species that rely on solar energy: oxygen and carbon dioxide. While phototrophs capture and store solar energy by transforming carbon dioxide into organic compounds and splitting water to emit oxygen, heterotrophs, such as human, consume such organic compounds as an energy source through "burning" or oxidation by oxygen with carbon dioxide and water as the ultimate end products of the organic component. Consequently, the reciprocal redox cycling of these two small gaseous molecules forms the chemical basis for powering life on earth that relies on solar energy. The story of nitrogen is just as intriguing; microorganism's ability to fix N 2 in organic molecules is another pillar that supports life on earth. Further, the products as a result of photosynthesis are also essential building blocks for the physical structure of life both in plants and in animals. At an individual organism level, the ability for humans to use oxygen for oxidation of organic molecules in a controlled fashion through an intricate web of enzymes is what allows us to capture the energy stored in these organic compounds and to survive on this earth. Even the byproduct, carbon dioxide, is not simply a waste or a bystander 2 ; it helps to regulate pH, stimulate breathing, and influence the hemoglobin's affinity for oxygen (the Bohr effect). While a small portion of carbon dioxide is transported as carbaminohemoglobin, carbonic anhydrase is the enzyme responsible for converting carbon dioxide into (bi)carbonate reversibly and is an important target for drug design for a variety of pathological conditions including cancer, neuropathic pain, fluid retention, epilepsy, and glaucoma, among others 3 . Beyond carbon dioxide and oxygen, three other gaseous molecules are recognized as endogenous signaling molecules in human: nitric oxide (NO) 4 , hydrogen sulfide (H 2 S) 5, 6 , and carbon monoxide (CO) 7, 8 . These three small signaling molecules are often referred to as "gasotransmitters" 9,10 , with some dissention 11 . They have similar and overlapping roles at times. Research on NO led to the 1998 Nobel prize in Physiology and Medicine being awarded to Robert F. Furchgott, Louis J. Ignarro and Ferid Murad for their seminal contributions. It is also important to note one thing. Though these three molecules are gaseous in the pure form under normal conditions, they largely exist in the body in the dissolved form, allowing for the possible interconversion of these two forms depending on location and conditions. These gaseous molecules also share three important traits: rapid diffusion, easy permeation through various barriers, and rapid excretion without the need for metabolism (especially CO) through exhalation. Among these three gaseous signaling molecules, NO has the shortest half-life, and thus is most suited for local signaling unless meta-stable precursors such as S-nitrosothiols are involved 12, 13 . HNO, the one-electron reduced and protonated congener of NO, exhibits some biological activities similar to that of NO 14 . Hydrogen sulfide is much more stable, but still undergoes rapid conversions to a variety of species through ionization, redox reactions, sulfur exchange, or chelation to metal ions 15, 16 . CO is relatively metabolic inert except for its high affinity for certain transition metals such as nickel 17 and iron 18 and undergoes minimal chemical transformation in mammalian cells under physiological conditions 19 , and thus is suitable for both local and global signaling over time as the biological half-life in humans is in the range of hours 20e23 . Recent years have seen sulfur dioxide (SO 2 ) emerging as a possible signaling molecule 24,25 . It is endogenously produced and has well-recognized biological functions. Another interesting gaseous molecule is molecular hydrogen (H 2 ) 26 , which has been extensively studied for its possible pharmacological effects 27 . To the best of our knowledge, there is no human enzyme that produces H 2 . Therefore, it would not be considered as an endogenous signaling molecule in the traditional sense. However, bacteria in the gut is known to produce H 2 28 . Then, could H 2mediated signaling be part of the bacteria-host symbiotic relationship? Furthermore, some pathogens also use H 2 as fuel, such as Helicobacter pylori. In terms of therapeutic application, it is very interesting to note that hydrogen-rich water is already commercially available in some parts of the world including China and Japan 26,29 . We defer to several excellent recent reviews for indepth discussions of this subject 26, 27, 29 . There are also other gaseous molecules in the body including CH 4 (gut bacteria) 28,30 , NH 3 31,32 , and N 2 33 that play various roles in normal human physiology. Available data on these gaseous species offers a complex and sophisticated picture of how a human body uses gaseous molecules for sustaining and controlling normal physiology. They also offer opportunities for developing therapeutic agents. Covering all these gaseous molecules would require more than a book. In this article, we start with one endogenous gaseous signaling molecules: carbon monoxide (CO)! Other stories will follow at a later time. Below we discuss the molecular, physiological, and pharmacological traits of CO. We will also briefly discuss some of CO's known molecular mechanisms of actions. As is true with everything is life, CO has two sides: it possesses very promising therapeutic utilities at low doses and is poisonous at high doses. Further, it is very important to point out that CO has a high enough safety margin for such applications. Fig. 1 summarizes the Yin and Yang sides of CO, the details of which are described in subsequent sections. In mammals, CO is produced mostly by heme degradation by an enzyme called heme oxygenase (HO) 34 , which has two enzymatically active isoforms (HO-1 and HO-2) and is present in all cells. Daily production of CO is on the scale of about 400 mmol per day 35 , largely as part of red blood cell turnover 35, 36 . However, there are other secondary sources including cytochrome P450 reductase 37 , human acireductone dioxygenase 38 , tyrosinase 39 , lipid peroxidation 40 , and numerous minor sources 36,41 . Further, microbiome sources of CO have not been extensively studied and could turn out to be very important in health and disease 42,43 . Regardless of the source, CO mostly exists in the form of carboxyhemoglobin (COHb) because of its 240-fold higher affinity to hemoglobin than oxygen and essentially reaches to all parts of the body through blood circulation. CO is known to be highly permeable and diffusible through both endothelium and skin epithelium 44,45 . There is strong evidence that orally administered CO donors allow delivery of CO into the systemic circulation 46,47 . Therefore, some common barriers for drug delivery, such as the intestinal barrier and bloodebrain barrier are not considered a major issue for CO, which is capable of diffusing in and out of the blood circulation. However, because of CO's affinity for hemoglobin, at any given time the proportion that diffuses into tissues is thought to be less than 20% 48 . CO is considered essential for life with multiple targets 49e52 ; and the physiological roles of the COeHO axis have been extensively studied over the past twenty years 53e55 . HO-1 is inducible in response to various stress signals and is cytoprotective and anti-inflammatory. During stress, increased production of CO is on the order of 4000 mmol per day 56 , which can be measured in exhaled breath 57e59 . Lack of HO-1 results in a pro-inflammatory phenotype. Though inflammation promotes malignant growth and contributes to cancer progression 60e65 , the effect of HO-1 on cancer is more complex than inflammation alone 66 . Further, HO-1 knockout animals were reported to die within a year with indications of inflammation in multiple organs, which is consistent with the known anti-inflammatory role of CO 67 . It is clear that CO is essential in sustaining life, has multiple targets and thus pleiotropic effects (see below), has high diffusivity, and is very stable. Therefore, CO's effect can be both local and global as well as long-lasting. Further, CO has overlapping targets and functions with NO and H 2 S. As a result, the study of CO's physiological and pharmacological functions needs to take a holistic approach by combining molecular-level details with global-level network interactions and feedback controls. 3. CO is known to be important in balancing human immunity and has anti-inflammatory, cytoprotective, and organ-protective effects One of the most widely studied properties of CO is its antiinflammatory, cytoprotective and organ-protective effects, with a large number of publications supporting this view 7, 8 . CO has been shown to be protective of organs such as kidney 68e71 , heart 72,73 , liver 74,75 , brain 76,77 , and gastrointestinal (GI) system 78e84 , among others 7, 8 after various injurious events such as ischemiaereperfusion injury, trauma, and chemically induced injury. Along a similar line, CO seems to show beneficial effects Figure 1 The Yin and Yang of CO. The left side (Yang) showcases the beneficial effects of CO and the top circle shows some of CO's therapeutic indications, either therapeutically delivered or endogenously produced through heme degradation by heme oxygenase (HO). The left side lists some of known CO's pharmacological targets (þpositive modulation; enegative modulation). The right side (Yin) highlights the toxic consequences of high-level exposure to CO-containing products from various sources. The higher binding affinity of CO over O 2 to respiratory hemeproteins such as hemoglobin, myoglobin, and neuroglobin compromises their ability to transport and store oxygen, leading to hypoxia and asphyxia. Persistent mitochondria dysfunction caused by cytochrome inhibition and disruption of NO signaling pathway by nitric oxide synthase inhibition also contributes to CO's toxicity in the central nervous system and cardiac system ( persistent inhibition). in treating autoimmune-related conditions 85e87 . In addition, CO has been examined in animal models of sickle cell disease 46 , preeclampsia 88,89 , and gastroparesis 90 and shown to have beneficial effects. The pleiotropic health effects of CO suggest its network-like pharmacological functions and speak to its unique traits and importance in maintaining overall human health. All these suggest the need to take a holistic approach to understanding CO's true physiological and pharmacological functions. One of the remarkable traits of CO is its ability to suppress pathologically relevant inflammation while still strengthening the body's ability to fend off infection and other pathological changes. This is very different from other anti-inflammation therapies such as corticosteroids and anti-tumor necrosis factor (TNF)-a agents. For example, CO has been shown to be beneficial in treating bacterial sepsis, which requires the ability to suppress inflammation while still allowing the body to fight off the infection 44,91,92 . In a recent study, Otterbein and colleagues 93 have shown that macrophages can sense CO and kill bacteria through activation of inflammasome. Similarly, CO blocks the proinflammatory cytokine TNF, while enhancing expression of the anti-inflammatory cytokine IL-10 in macrophages and in tissue 94, 95 . CO likewise has a direct manner of action against pathogens by inhibiting bacterial oxidases and essential hemoproteins 96 . In the area of cancer, CO has been shown to sensitize cancer cells toward chemotherapy 64,97 through an anti-Warburg effect, and to help overcome cisplatin resistance 98, 99 , while simultaneously offer protection of organs such as the heart, kidney, and liver that are prone to chemically-induced injuries 72,100e105 . Very few, if any, known therapies can offer such seemingly directional controls in achieving therapeutic effects. One can also say that CO helps to restore a balance in eradicating pathological changes. Pre-conditioning 106 and remote ischemic conditioning (RIC) 107,108 refer to the protective effects of relatively minor ischemic events either locally beforehand or remotely against major damages resulting from ischemia-related events 109, 110 . Despite success in some studies and in pre-clinical models 111e116 , not all studies observed the same benefit of such conditioning 117e120 . Thus, a deeper understanding of the mechanism of action might offer a chance to elucidate critical factors that contribute to success in such conditioning and may lead to approaches for pharmacological conditioning 121 . Mechanistic studies in animal models have led to suggestions of involvement of NO 122 , hypoxia-inducible factor 1a (HIF-1a) 123, 124 , the PTEN/ AKT signaling pathway 124 , exosomal miR-21 125 , NF-kB 126e128 , and IkBa 129 in pre-conditioning or RIC. Understandably, many such molecular targets are inter-related. No matter what the mechanism is, RIC will likely involve the diffusion of a "signal" from a remote site to the location where ischemic damage happens. CO is such a molecule. HO-1 has been suggested as playing a key role in anesthetic-induced conditioning 130 and CO has been suggested as a mediator in the conditioning process 131, 132 . In an animal model study, it was shown that inhalation of CO was able to recapitulate the HO-1 induced protective conditioning in a liver ischemic reperfusion injury model 133 . As discussed in Section 2, there have been many other reports of CO's role in organ protection after ischemic reperfusion injury 134e136 . Thus, HO-1 activation and CO production as a result of minor and repeated ischemic events at a remote site could lead to the protection of major ischemic injuries through distance. Again, the chemically inert nature, diffusivity, and long half-life of CO play an important role in allowing CO to be a signaling molecule through distance and over time. 6. There is a large amount of data allowing for some understanding of CO's molecular mechanism(s) of actions The examination of CO's pleiotropic pharmacological effects is supported by extensive and rigorous mechanistic studies, which are very critical to the advancement of this field. Some of the identified molecular targets of CO include the soluble form of guanylyl cyclase, mitochondrial oxidases, nitric oxide synthases, prolyl hydroxylase, neuronal PAS domain protein 2 (NPAS2), the CLOCK transcription factor, Per-2, mitogen-activated protein (MAP) kinases, catalase, PPARg, HIF-1a, Nrf2, ion channels, and cystathionine b-synthase (CBS), among others 71,95,101,137e141 . A detailed discussion of this aspect would require a separate paper or a book. However, the references provided hopefully would allow readers to delve into the details, should they be interested. The multi-target nature of CO is very remarkable. Understanding the intricate interplay among all the molecular targets in a holistic fashion will be very valuable to achieve a deeper understanding of the "network" effect of CO, especially considering that CO has overlapping targets and functions with NO and H 2 S. Fortunately, this area has attracted a great deal of attention and research activities 9,10 . 7. CO has healing powers, is safe at therapeutic levels, and yet is harmful or lethal at high levels Although CO plays an essential role in human physiology in managing inflammation as one of its functions and is being developed for therapeutic applications, there is no doubt that CO is toxic or lethal at high levels. Although the highest recorded nonfatal COHb was 73% 142 , each year many people die of CO poisoning 143 . Therefore, it is very important to understand the normal physiological concentration range and safety margin of CO. In non-smokers, COHb levels averaged about 2% in one study, while smokers averaged 8% 144 . Hookah smoking has been the subject of clinical trials based on the link between CO inhalation and its vasodilatory mechanism of action (NCT03067701). Interestingly, despite the overall harmful effect of cigarette smoking, some studies found an inverse correlation between smoking and incidents of ulcerative colitis 145e147 while others offer a different view 148e150 . Animal model experiments have also duplicated the inverse relationship between smoking and ulcerative colitis 151, 152 . Further research points to CO's beneficial effects in colitis as a likely molecular link and suggests that the COHb level achieved through smoking is high enough for therapeutic values, though one has to be mindful of all the other harmful substance inhaled during smoking 79e82,84,152e154 . If one considers the fact that Hb level in a healthy person is about 7.5 mmol/L, the CO concentration in the form of COHb in the blood can range from 150 (non-smokers) to 600 mmol/L (smokers), which is within human safety tolerance. These concentrations are also comparable to or higher than the peak plasma concentrations of approved drugs such as Tylenol (>100 mmol/L), naproxen (>300 mmol/L), Zantac (1.5 mmol/L), doxorubicin (1e2 mmol/L) 155 , imatinib (3.5 mmol/L), and 5-fluorouracil (>300 mmol/L). As a matter of fact, CO has been studied for safety in several human clinical trials. As a result, the U.S. Food and Drug Administration has approved clinical trials with COHb level being as high as 14% as an upper threshold 105 . All indications are that CO can be developed as a safe therapeutic agent with safety margins being higher or comparable to even nutrients such as glucose and potassium as well as therapeutics such as insulin, heparin, digitalis, warfarin, and others 7, 133 . Herein lies an important message that is not always as widely understood in the general public as one would have hoped. As an important historical figure, Paracelsus (a Swiss physician, alchemist, and philosopher, 1493e1541) would say, it is the dose that makes a poison or a remedy 156 . CO's therapeutic effect at low doses does not diminish its health risk or lethality at high levels, and vice versa. Further, simply because a drug is useful in treating a specific pathological condition does not mean that it is good for a healthy person to take as a preventative measure. This is a message that I (Wang) always tell students: just because taxol is a good drug to treat certain forms of cancer, it does not mean that a healthy person should take taxol to prevent the same cancer because all drugs are inherently toxic if abused. The same message is true for CO as well as medicinal plants, herbal supplements, and natural compounds. Prophylactic usage is very different from treatment and should only be based on proven science. Just because CO has the potential to be used as a therapeutic agent for treating certain conditions such as inflammation, it does not mean that a healthy person can "self-medicate" in any form or fashion. All therapeutic agents should be used only based on clinically proven science and under the supervision of appropriately trained medical professionals. Otherwise, there could be harmful or lethal consequences. Because of the demonstrated pharmacological activity of CO, there is much interest in developing CO-based therapeutics for various indications, as summarized in a few recent reviews 7,8,157e160 . Thus, we shall only provide a brief synopsis without duplicating what is in these reviews. In addition to efficacy, there are two key factors to consider in developing CO-based therapeutics: toxicity and delivery. For toxicity, Sections 1 and 6 specifically address this issue. Three recent reviews address the safety issue in detail and show that for pharmaceutical development, CO has a sufficient safety margin, which is probably higher than or comparable to many approved therapeutics 105, 160, 161 . For delivery, using CO gas as the delivery form actually poses several issues. First, CO is lethal at high doses. A practical problem in using CO in a tank is that it is odorless, colorless, and tasteless, making it hard to detect if leakage happens. Even with the availability of CO detectors, CO leakage still poses a safety issue for healthcare workers and family members in the same household. Further, delivering a precise dose of gaseous CO through inhalation is a challenge by itself and in terms of patient compliance. As a result, there have been strong interests in developing alternative CO delivery methods including oral formulations and metal-immobilized carbonyls as CO-releasing molecules (CORMs) 159 . For those who are interested in more details, there are two earlier reviews and three recent reviews that cover the subject comprehensively 8,158e160,162 . Recent years have seen a growing interest in developing metal-free CO prodrugs belonging to different structural scaffolds 7,158,161e169 . These include prodrugs with tunable release rates (2 min to days) 153, 162, 165, 170 , targeted delivery 75,171,172 , triggered release (pH-173e175 , reactive oxygen species (ROS)-176 , thiol-177 , esterase-sensitive 174, 178 , photo-sensitive 164,167e169,172,179 as well as dual-triggered 166, 174, 177 prodrugs), the ability to deliver two payloads in one prodrug 180 , and the ability to target the mitochondria 75,158,171 . These prodrugs have shown anti-inflammatory 162 and antibacterial (H. pylori) 180 effects in vitro and have been studied in animal models of colitis 153 , gastric injuries 181 , liver injuries 75,174 , kidney injuries 71 , and systemic inflammation 174 with very pronounced efficacy. Fig. 2 71,75,153,161,164e168,170,173 ,175e177,180,104,169,182e200 summarizes the conceptual development of CO delivery forms; and we hope that with this many CO delivery options available, some will eventually be developed into therapeutic agents. Even with all the remarkable progress, it is important to note that challenges remain in areas such as (1) understanding the interplay of dosage, duration of exposure, and efficacy, (2) deciding key parameters to measure in studying CO's pharmacokinetics 47 , (3) tissue-specific delivery when needed, (4) ways to minimize systemic CO exposure when needed, (5) methods for real-time detection of free and bound CO, and (6) a deeper understanding of the consequence of the "network"-like pleiotropic effects of CO at the molecular level. Recently, it has been reported that many of the previously described biological effects of metal-based CORMs, including antimicrobial 201e205 , anticoagulation 206e208 , and ion channel regulation 209 are actually CO independent. Instead, much of these activities can be attributed to the generation of reactive oxygen species 203e205 , and reactivity toward thiol 201 , sulfite 210 , proteins and enzymes 201,208,209,211e217 , and electron-deficient organic functional groups such as an arylnitro group 218 by certain metalbased CORMs in as well as their general solution chemistry including water-shift reactions 203, 219 . All these issues indeed suggest that some of these metal-based CORMs may be more than CO donors per se. Such results further suggest the need to use rigorous controls and assessment of the general molecular reactivity of CO donors and their side products after CO release, whether they are metal-based CORMs or organic prodrugs. Therefore, much more work is needed. In discussing CO-based therapeutics, it is critical to also analyze one issue: pharmacokinetics. As discussed earlier, CO's biological half-life (t 1/2 ) in humans is commonly cited as about 300 min under atmospheric conditions 20 . However, such studies were mostly in the context of CO poisoning, presumably through inhalation. One may also need to consider the likelihood that the t 1/2 may vary depending on the duration of CO exposure and alveolar ventilation 220 , the form of CO delivery 47, 221, 222 , and the level of CO in the blood 21e23,223e228 . For example, in a study of human waterpipe usage, COHb level (averaging 6.2% COHb) returned to the baseline level within 8 h, implying a t 1/2 of much shorter than 300 min 229 . In any case, CO administration in the form of short inhalation of 1000 ppm (once every min for 10 min) at 40 min interval was sufficient to give a sustain level of COHb 230 . In most animal model studies, once daily administration of CO is commonly used for yielding pharmacological efficacy. However, the biological half-life of CO as represented by COHb levels seems to vary considerably among porcine, dog, rabbit, rodent, and human 231e234 . For example, in mice when administered in the form of CO prodrugs, the t 1/2 of COHb is normally about 1e2 h depending on the route of administration 47,75 . In porcine after bolus administration of CO-saturated blood, the t 1/2 of COHb is also about 1 h 235 . There have been other pharmacokinetic studies of COHb profiles using different donors and under different conditions 8, 229 . Such results mean that much more work is needed in examining the relationship between pharmacokinetics and pharmacodynamics, which may vary depending on the specific pharmacological indications. With all the discussions above, it is clear that CO is essential to human health, has a wide range of pharmacological effects, and has therapeutic potential. The inter-twined pleiotropic effects of CO mean that we will need to take an integrated and holistic approach to understanding CO's functional roles, especially in the context of its overlapping functions with NO and H 2 S. Beyond CO, it is important to note the network-like roles of the various gaseous molecules in sustaining life. This is an area that will require elevated levels of activities to fully tap into the therapeutic potential of these gaseous molecules. As an afterthought, it is important to note that the conception of the roles of gaseous molecules in life's processes did not start with the commencement of modern molecular science. Quite to the contrary, the central roles that gaseous entities play in life had been recognized long time ago by human ancestors throughout the ancient civilizations, even though at that time, understanding at the molecular level was in the far distant future. For example, more than five thousand years ago in the ancient India, breath and gas (prana, "प् राण" in Hindu) were acknowledged as a vital element for life in the oldest philosophical medicine system known as "Ayurveda" 236 . Further, the book On Medicine, published around 100 AD, describes how Hippocrates (460e370 BC), the Greek physician often considered as the father of medicine, conjures the role of breaths and gases (pneuma, "pnεṽma" in Greek) in health and disease. In a similar period of time, the concept of "Qi" (or Chi, "氣" in traditional Chinese) also emerged in Chinese medical records such as the "The Yellow Emperor's Classic of Medicine" (circa 2nd century BCE). However, all these ancient concepts seem to have a broader meaning than its literal translation of the physical concept of "air" or "gas" and to embody philosophical concepts as well, reflecting the recognition of the vital nature of gaseous entities in life. Finally, it is also interesting to note that one of the earliest medicines that continues its use in the modern days is laughing gas, or nitrous oxide, which was first introduced in the 1770's 237 . It is our hope that this article will serve as a teaser to nature's marvels embedded in gaseous molecules and will help to stimulate additional interests in the same. As a result, we look forward to seeing a boom in research activities in this area so that we can collectively take a quantum leap in moving this field forward. We also hope that readers will lend their collective wisdom to the exploration of the holistic roles of gaseous signaling molecules in maintaining human health. We acknowledge the general financial support of the Georgia Research Alliance through an Eminent Scholar endowment and internal financial sources at Georgia State University, USA. CPH's work was supported by The German Research Foundation (Deutsche ForschungsgemeinschaftdDFG), Germany, grant number: DFG #374031971 CRC/TR 240, Projekt B03. We would also like to express our gratitude to many friends and colleagues, who shall remain anonymous, for their thoughtful personal counsel, insightful advice, and constructive suggestions during the preparation of this manuscript. Xiaoxiao Yang and Binghe Wang drafted this manuscript. Christopher P. Hopper, Wen Lu, and Bowen Ke gave their intellectual input and revised the manuscript. 14) and (15) Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide Physiological carbon dioxide, bicarbonate, and pH sensing Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas Nitric oxide is not just blowing in the wind Hydrogen sulfide and polysulfide signaling Gasotransmitter hydrogen sulfide signaling in neuronal health and disease Toward carbon monoxide-based therapeutics: critical drug delivery and developability issues The therapeutic potential of carbon monoxide Pharmacology of the 'gasotransmitters' NO, CO and H 2 S: translational opportunities Gasotransmitters and the immune system: mode of action and novel therapeutic targets Do nitric oxide, carbon monoxide and hydrogen sulfide really qualify as 'gasotransmitters' in bacteria? RSNHO * : the structure of the SNO moiety in "S-nitrosohemoglobin", a possible NO reservoir and transporter Nitrosothiol formation and S-nitrosation signaling through nitric oxide synthases A recent history of nitroxyl chemistry, pharmacology and therapeutic potential Sulfur as a signaling nutrient through hydrogen sulfide Toward hydrogen sulfide based therapeutics: critical drug delivery and developability issues Nonredox nickel enzymes Carbon monoxide binding to iron porphyrins Metabolism of carbon monoxide Hyperbaric treatment of carbon monoxide Carbon monoxide reverses diabetic gastroparesis in NOD mice Carbon monoxide improves efficacy of mesenchymal stromal cells during sepsis by production of specialized proresolving lipid mediators Exogenous carbon monoxide decreases sepsis-induced acute kidney injury and inhibits NLRP3 inflammasome activation in rats Macrophages sense and kill bacteria through carbon monoxidedependent inflammasome activation Carbon monoxide inhibits tenascin-C mediated inflammation via IL-10 expression in a septic mouse model Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway Carbon monoxide in biology and microbiology: surprising roles for the "Detroit perfume Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein Reaction of carbon monoxide with cystathionine beta-synthase: implications on drug efficacies in cancer chemotherapy Renoprotective effects of carbon monoxide-releasing molecule 3 in ischemiaereperfusion injury and cisplatin-induced toxicity Protection against cisplatin-induced nephrotoxicity by a carbon monoxidereleasing molecule CO liberated from a carbon monoxide-releasing molecule exerts a positive inotropic effect in doxorubicin-induced cardiomyopathy Beneficial effects of carbon monoxide-releasing molecule-2 (CORM-2) on acute doxorubicin cardiotoxicity in mice: role of oxidative stress and apoptosis Cardioprotective actions by a water-soluble carbon monoxidereleasing molecule Carbon monoxide: an emerging therapy for acute kidney injury Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Remote ischaemic conditioningda new paradigm of self-protection in the brain Remote ischemic conditioning for stroke: clinical data, challenges, and future directions Remote ischemic preconditioning: the hunt is still open Protecting the heart from ischemia/reperfusion injury: an update on remote ischemic preconditioning and postconditioning Remote ischemic preconditioning prevents postoperative acute kidney injury after open total aortic arch replacement: a double-blind, randomized, sham-controlled trial Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial Long-term effects of remote ischemic preconditioning on kidney function in high-risk cardiac surgery patients: follow-up results from the RenalRIP trial Remote ischemic preconditioning and protection of the kidneyda novel therapeutic option Ischaemic and hypoxic conditioning: potential for protection of vital organs Cardioprotection via the skin: nociceptor-induced conditioning against cardiac MI in the NIC of time Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery) Remote ischaemic conditioning for preventing and treating ischaemic stroke Remote ischemic preconditioning in microsurgical head and neck reconstruction: a randomized controlled trial Effects of ischemic preconditioning on abdominal aortic aneurysm repair: a systematic review and meta-analysis Remote ischemic preconditioning for kidney protection: GSK3beta-centric insights into the mechanism of action The effect of nitric oxide on remote ischemic preconditioning in renal ischemia reperfusion injury in rats Hypoxiainducible factor 1alpha and 2alpha have beneficial effects in remote ischemic preconditioning against stroke by modulating inflammatory responses in aged rats Remote ischemic preconditioning protects cisplatin-induced acute kidney injury through the PTEN/AKT signaling pathway Delayed remote ischemic preconditioning confers renoprotection against septic acute kidney injury via exosomal miR-21 Remote ischemic preconditioning prevents lipopolysaccharide-induced liver injury through inhibition of NF-kappaB activation in mice Remote ischemic preconditioning and diazoxide protect from hepatic ischemic reperfusion injury by inhibiting HMGB1-induced Preactivation of Notch1 in remote ischemic preconditioning reduces cerebral ischemiaereperfusion injury through crosstalk with the NF-kappaB pathway Remote ischemic preconditioning ameliorates indirect acute lung injury by modulating phosphorylation of IkappaBalpha in mice The role of heme oxygenase-1 in remote ischemic and anesthetic organ conditioning The role of gasotransmitters NO, H 2 S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning Heme oxygenase and carbon monoxide initiate homeostatic signaling Therapeutic applications of carbon monoxide-releasing molecules Inhaled carbon monoxide provides cerebral cytoprotection in pigs Cytoprotection by inhaled carbon monoxide before cardiopulmonary bypass in preclinical models Use of carbon monoxide in minimizing ischemia/reperfusion injury in transplantation Biological signaling by carbon monoxide and carbon monoxide-releasing molecules Carbon monoxide induced PPARgamma SUMOylation and UCP2 block inflammatory gene expression in macrophages Carbon monoxide orchestrates a protective response through PPARgamma Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species NPAS2: a gas-responsive transcription factor Carboxyhemoglobin: a primer for clinicians Carbon monoxide poisoning Smoking fewer than 20 cigarettes per day and remaining abstinent for more than 12 hours reduces carboxyhemoglobin levels in packed red blood cells for transfusion Cigarette smoking associates inversely with a cluster of two autoimmune diseases: ulcerative colitis and pemphigus Smoking and digestive tract: a complex relationship. Part 1: inflammatory bowel disease and cigarette smoking Smoking in inflammatory bowel diseases: good, bad or ugly? Smoking and risk of microscopic colitis: a systematic review and meta-analysis Smoking is associated with an increased risk of microscopic colitis: results from two large prospective cohort studies of US women Medical vulnerability of young adults to severe COVID-19 illnessddata from the national health interview survey Protective effect of cigarette smoke on the course of dextran sulfate sodium-induced colitis is accompanied by lymphocyte subpopulation changes in the blood and colon The reduction of DSS-induced colitis severity in mice exposed to cigarette smoke is linked to immune modulation and microbial shifts Click and release: a chemical strategy toward developing gasotransmitter prodrugs by using an intramolecular DielseAlder reaction Colonic insufflation with carbon monoxide gas inhibits the development of intestinal inflammation in rats Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass Paracelsus revisited: the dose concept in a complex world Where is the clinical breakthrough of heme oxygenase-1/carbon monoxide therapeutics? Extracellular vs intracellular delivery of CO: does it matter for a stable, diffusible gasotransmitter? CO-releasing molecules: a personal view CO as a therapeutic agent: discovery and delivery forms Delivery of carbon monoxide via halogenated ether anesthetics Strategies toward organic carbon monoxide prodrugs Click and release: bioorthogonal approaches to "on-demand" activation of prodrugs 3-Hydroxyflavones and 3-hydroxy-4-oxoquinolines as carbon monoxide-releasing molecules A structurally-tunable 3-hydroxyflavone motif for visible light-induced carbon monoxide-releasing molecules (CORMs) CO sense and release flavonols: progress toward the development of an analyte replacement PhotoCORM for use in living cells Visible-light activatable organic CO-releasing molecules (PhotoCORMs) that simultaneously generate fluorophores Transition-metal-free CO-releasing BODIPY derivatives activatable by visible to NIR light as promising bioactive molecules Fluorescein analogue xanthene-9-carboxylic acid: a transition-metal-free CO releasing molecule activated by green light Organic COprodrugs: structure co-release rate relationship studies Mitochondrial-localized versus cytosolic intracellular CO-releasing organic PhotoCORMs: evaluation of co effects using bioenergetics Visible-light-activated quinolone carbon-monoxide-releasing molecule: prodrug and albumin-assisted delivery enables anticancer and potent anti-inflammatory effects pH-sensitive metal-free carbon monoxide prodrugs with tunable and predictable release rates Esterasesensitive and pH-controlled carbon monoxide prodrugs for treating systemic inflammation Norborn-2-en-7-ones as physiologically-triggered carbon monoxide-releasing prodrugs Organic CO Prodrugs activated by endogenous ROS Sense and release: a thiol-responsive flavonol-based photonically driven carbon monoxide-releasing molecule that operates via a multiple-input AND logic gate An esterase-activated click and release approach to metal-free CO-prodrugs Mechanism of the cyclopropenone decarbonylation reaction. A density functional theory and transient spectroscopy study Click, release, and fluoresce: a chemical strategy for a cascade prodrug system for codelivery of carbon monoxide, a drug payload, and a fluorescent reporter Organic carbon monoxide prodrug, BW-CO-111 in protection against chemically induced gastric mucosal damage Clinical trials: NCT00122694, NCT02425579, NCT01214187, NCT01523548 Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study Evaluation of inhaled carbon monoxide as an antiinflammatory therapy in a nonhuman primate model of lung inflammation Effects of carbon monoxide inhalation during experimental endotoxemia in humans HBI-002 CO drink; HBI-137 CO infusion Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities Dicarbonyl-bis(cysteamine)iron(II): a light induced carbon monoxide releasing molecule based on iron (CORM-S1) Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (TPM) manganese tricarbonyl complex ClO 4 ) 2 : photoactivated carbon monoxide release, growth inhibitory activity, and peptide ligation Polymer conjugates of photoinducible co-releasing molecules Lighttriggered CO delivery by a water-soluble and biocompatible manganese photoCORM CORM-A1: a new pharmacologically active carbon monoxidereleasing molecule Design, synthesis, and functional evaluation of CO-releasing molecules triggered by Penicillin G amidase as a model protease Acyloxybutadiene iron tricarbonyl complexes as enzyme-triggered CO-releasing molecules (ET-CORMs) HYCO-3, a dual CO-releaser/Nrf2 activator, reduces tissue inflammation in mice challenged with lipopolysaccharide CO release with ratiometric fluorescence changes: a promising visible-light-triggered metal-free CO-releasing molecule A clickand-release approach to CO prodrugs Click and fluoresce: a bioorthogonally activated smart probe for wash-free fluorescent labeling of biomolecules An esterase-activated click and release approach to metal-free CO-prodrugs A thiol-reactive Ru(II) ion, not CO release, underlies the potent antimicrobial and cytotoxic properties of COreleasing molecule-3 The broad-spectrum antimicrobial potential of [Mn(CO) 4 (S 2 CN-Me(CH 2 CO 2 H))], a water-soluble co-releasing molecule (CORM-401): intracellular accumulation, transcriptomic and statistical analyses, and membrane polarization An N-acetyl cysteine ruthenium tricarbonyl conjugate enables simultaneous release of CO and ablation of reactive oxygen species Reactive oxygen species mediate bactericidal killing elicited by carbon monoxide-releasing molecules A role for reactive oxygen species in the antibacterial properties of carbon monoxide-releasing molecules not carbon monoxide, inhibits the procoagulant activity of Atheris, Echis, and Pseudonaja venoms Mechanisms responsible for the anticoagulant properties of neurotoxic dendroaspis venoms: a viscoelastic analysis The anticoagulant effect of Apis mellifera phospholipase A 2 is inhibited by CORM-2 via a carbon monoxide-independent mechanism CO-independent modification of K þ channels by tricarbonyldichlororuthenium(II) dimer (CORM-2) Sulfite species enhance carbon monoxide release from CO-releasing molecules: implications for the deoxymyoglobin assay of activity Towards improved therapeutic CORMs: understanding the reactivity of CORM-3 with proteins New insights into the chemistry of fac-[Ru(CO) 3 ] 2þ fragments in biologically relevant conditions: the CO releasing activity of CORM-3 reactivity toward proteins: the crystal structure of a Ru(II) dicarbonyl-lysozyme complex Ru-based CO releasing molecules with azole ligands: interaction with proteins and the CO release mechanism disclosed by X-ray crystallography A contribution to the rational design of Ru(CO) 3 Cl 2 L complexes for in vivo delivery of CO Formation of high molecular weight p62 by CORM-3 Interaction of carbon monoxide-releasing ruthenium carbonyl CORM-3 with plasma fibronectin Nitro reduction-based fluorescent probes for carbon monoxide require reactivity involving a ruthenium carbonyl moiety Metal carbonyls as pharmaceuticals? A simple "new" method to accelerate clearance of carbon monoxide PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial The influence of small doses of carbon monoxide upon heart rate Replicating measurements of total hemoglobin mass (tHb-mass) within a single day: precision of measurement; feasibility and safety of using oxygen to expedite carbon monoxide clearance Toxicological interactions between carbon monoxide and carbon dioxide Carbon monoxide uptake kinetics of arterial, venous and capillary blood during CO rebreathing A multicompartment model of carboxyhemoglobin and carboxymyoglobin responses to inhalation of carbon monoxide Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers Alterations in pharmacokinetics of carboxyhemoglobin produced by oxygen under pressure Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo Cardiovascular effects of carbon monoxide and cigarette smoking Experimental exposure to carbon monoxide in rats (I)drelation between the degree of carboxyhemoglobin saturation and the amount of carbon monoxide in the organ tissues of rats Prediction of the carbonmonoxyhemoglobin levels during and after carbon monoxide exposures in various animal species Factors influencing carboxyhemoglobin kinetics in inhalation lung injury Elimination of CO from the body: an experimental study on the rabbit Circulatory effects and kinetics following acute administration of carbon monoxide in a porcine model Mind in ayurveda Drug discovery: a history The authors declare no conflicts of interest.